Fundraising FoxSphera Funds Management — 2019 Investments
2 investments dated 2019 · listed companies and verified rows first · show all
Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.
BiotechHealthtechPhiladelphia, US
William Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)in
BoardPatrick Heron(Director)inCarl Gordon(Director)inThomas Street Address 1 Woiwode(Director)
Co-investorsFrazier Life SciencesAccess BiotechnologyFrazier Healthcare PartnersLilly Asia VenturesNew Leaf Venture PartnersOrbiMed+2 more
Cambridge, US
Christophe Queva(Executive Officer)inTheodore Ashburn(Executive Officer, Director)Alon Lazarus(Director)Cameron Wheeler(Director)in
BoardBriggs Morrison(Director)inMitchell Finer(Executive Officer, Director)
Co-investorsAstellas Venture Management LLCCowen Healthcare InvestmentsDeerfield Management CompanyIMM InvestmentK2 HealthVenturesMPM BioImpact
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.